- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | H.C. Wainwright raises Alpha Tau Medical stock price target to $16 | 1 | Investing.com | ||
| Mi | H.C. Wainwright hebt Kursziel für Alpha Tau Medical auf 16 $ an | 2 | Investing.com Deutsch | ||
| ALPHA TAU MEDICAL Aktie jetzt für 0€ handeln | |||||
| Mo | Alpha Tau Medical GAAP EPS of -$0.25 | 1 | Seeking Alpha | ||
| Mo | Alpha Tau Medical Ltd.: Alpha Tau Announces Second Quarter 2026 Financial Results and Provides Corporate Update | 157 | GlobeNewswire (Europe) | - Groundbreaking interim results from the U.S. recurrent glioblastoma REGAIN trial demonstrated 100% local disease control and a 67% complete response rate, followed by FDA clearance to complete trial... ► Artikel lesen | |
| Mo | Alpha Tau plans dual listing on Nasdaq and TASE to expand access for Israeli investors | 3 | Seeking Alpha | ||
| Mo | Alpha Tau Medical Ltd.: Alpha Tau Registers for Dual Listing on the Tel Aviv Stock Exchange (TASE) | 1 | GlobeNewswire (USA) | ||
| Mo | Alpha Tau Medical Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 23.07. | H.C. Wainwright reiterates Alpha Tau Medical stock rating at buy | 1 | Investing.com | ||
| 21.07. | Alpha Tau rises on Alpha DaRT head and neck cancer data | 2 | Seeking Alpha | ||
| 21.07. | Alpha Tau reports positive trial results for cancer therapy combo | 4 | Investing.com | ||
| 21.07. | Alpha Tau meldet positive Studienergebnisse für kombinierte Krebstherapie | 1 | Investing.com Deutsch | ||
| 21.07. | Alpha Tau Medical Ltd.: Alpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRT in Combination with Pembrolizumab in Locally Advanced or Metastatic Head and Neck Cancer, ... | 274 | GlobeNewswire (Europe) | - Podium presentation at the American Head and Neck Society (AHNS) 12th International Conference on Head and Neck Cancer to report results from a study of Alpha DaRT in combination with pembrolizumab... ► Artikel lesen | |
| 17.07. | H.C. Wainwright reiterates Alpha Tau Medical stock rating on immunocompromised patient treatment | 1 | Investing.com | ||
| 17.07. | H.C. Wainwright bestätigt Rating für Alpha Tau Medical nach Behandlungserfolg bei immunsupprimierten Patienten | 2 | Investing.com Deutsch | ||
| 15.07. | Alpha Tau Medical Ltd.: Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer Center | 233 | GlobeNewswire (Europe) | - The ADMIRE study, by treating immunocompromised patients, builds on the momentum of Alpha Tau's ReSTART pivotal trial for recurrent cSCC, which recently completed patient enrollment, under which... ► Artikel lesen | |
| 15.07. | Alpha Tau Medical Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 23.06. | Alpha Tau Medical Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 23.06. | Alpha Tau Medical Ltd.: Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT at Hadassah University Medical Center in Israel | 374 | GlobeNewswire (Europe) | - First glioblastoma patient ever treated with Alpha DaRT® outside of the United States, and the first in Israel - performed at Hadassah University Medical Center in Jerusalem, one of the world's... ► Artikel lesen | |
| 15.06. | H.C. Wainwright reiterates Alpha Tau Medical stock rating on FDA trial clearance | 1 | Investing.com | ||
| 15.06. | H.C. Wainwright bestätigt Kaufempfehlung für Alpha Tau Medical nach FDA-Zulassung für Studie | 1 | Investing.com Deutsch |
1 2 3 4 Weiter >>
72 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ATOSSA THERAPEUTICS | 2,160 | -1,82 % | Atossa Therapeutics Inc: Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update | SEATTLE, Aug. 7, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel... ► Artikel lesen | |
| BUTTERFLY NETWORK | 7,589 | -1,08 % | Butterfly Network, Inc. - 8-K, Current Report | ||
| BEYOND AIR | 6,990 | +1,01 % | Beyond Air Reports Financial Results for the Quarter Ended June 30, 2026 and Provides Corporate Update | Reports $1.8 million revenue for quarter ended June 30, 2026; reaffirms revenue guidance of $8 million for CY2026 and $16-$18 million for CY2027 PMA supplement for second-generation LungFit PH system... ► Artikel lesen | |
| AXOGEN | 42,350 | +1,61 % | Axogen, Inc. Reports Second Quarter 2026 Financial Results | ALACHUA, Fla. and TAMPA, Fla., July 29, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral... ► Artikel lesen | |
| AETHLON MEDICAL | 2,970 | 0,00 % | Aethlon Medical, Inc.: Aethlon Medical Reports Q1 Fiscal 2027 Results and Progress on Hemopurifier Program | Conference Call Today at 4:30 p.m. ET
SAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (Nasdaq: AEMD), a clinical-stage medical... ► Artikel lesen | |
| AVANOS MEDICAL | 21,600 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 27.07.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 27.07.2026.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 27.07.2026.ISIN NameCA05335P1099 AUXLY... ► Artikel lesen | |
| TACTILE SYSTEMS TECHNOLOGY | 21,620 | +5,05 % | Tactile Medical projects $360M-$366M 2026 revenue as airway clearance ordering normalizes in Q4 | ||
| HYDREIGHT TECHNOLOGIES | 2,395 | -0,21 % | Victory Square Technologies Inc: Victory Square Provides Update on Hydreight and Healthcare Investments Following FDA Advisory Committee Recommendations on Peptide-Related Bulk Drug Substances | VANCOUVER, BC, July 29, 2026 /PRNewswire/ -- Victory Square Technologies Inc. ("Victory Square", "VST" or the "Company") (CSE: VST) (OTCQX: VSQTF) (FWB: 6F6) is... ► Artikel lesen | |
| APYX MEDICAL | 2,620 | -0,76 % | Apyx Medical Corp - 8-K, Current Report | ||
| ANGIODYNAMICS | 13,500 | -0,74 % | AngioDynamics auf Canaccord Genuity Konferenz: Strategiewechsel zu MedTech-Wachstum wird vertieft | ||
| ANTERIS TECHNOLOGIES GLOBAL | 8,940 | 0,00 % | Anteris Technologies Global Corp.: Anteris Technologies Announces Results for the Second Quarter of 2026 | MINNEAPOLIS and BRISBANE, Australia, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. ("Anteris" or the "Company") (NASDAQ: AVR, ASX: AVR) a global healthcare company committed... ► Artikel lesen | |
| ADAPTHEALTH | 5,710 | +0,18 % | Morning Market Movers: Ameresco, Inno Holdings, AdaptHealth, Ibotta See Big Swings | OTTAWA (dpa-AFX) - At 7:50 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| AUTONOMIX MEDICAL | 6,860 | 0,00 % | Autonomix Medical, Inc.: Autonomix Medical Completes Good Laboratory Practice (GLP) Preclinical Study, Marking Key Step Toward FDA Submission | ||
| BLUEJAY DIAGNOSTICS | 1,050 | 0,00 % | Bluejay Diagnostics, Inc.: Bluejay Diagnostics Reports Q2 2026 Results; Strengthened Balance Sheet Supports Advancement of Symphony IL-6 Toward Regulatory Submission and Commercialization | SYMON-II pivotal clinical study completes targeted enrollment of 750 patientsCompany advances toward planned 510(k) submission and commercialization with US manufacturing contract signed to mitigate... ► Artikel lesen | |
| AGAPE ATP | 2,525 | +1,00 % | Morning Market Movers: Intercont (Cayman), Agape ATP, Astrotech, Snowflake See Big Swings | TOKYO (dpa-AFX) - At 8:05 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen |
Das Unternehmen ALPHA TAU MEDICAL LTD kann der Branche Gesundheitswesen zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 14,500 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALPHA TAU MEDICAL LTD finden Sie auf Wallstreet Online.